NCT00652938View on ClinicalTrials.gov

Evaluation of Immunogenicity and Safety of Human Papillomavirus (HPV) Vaccine Co-administered With Another Vaccine in Healthy Female Subjects

PHASE3CompletedINTERVENTIONAL
Enrollment

744

Participants

Timeline

Start Date

April 9, 2008

Primary Completion Date

August 28, 2009

Study Completion Date

January 8, 2010

Conditions
Infections, Papillomavirus
Interventions
BIOLOGICAL

HPV Vaccine (GSK580299) Cervarix TM

IM administration

BIOLOGICAL

Engerix B

IM administration

Trial Locations (7)

6525 GA

GSK Investigational Site, Nijmegen

3011 EN

GSK Investigational Site, Rotterdam

SE-581 85

GSK Investigational Site, Linköping

SE-972 31

GSK Investigational Site, Luleå

SE-211 52

GSK Investigational Site, Malmo

SE-601 82

GSK Investigational Site, Norrköping

SE-511 62

GSK Investigational Site, Skene

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00652938 - Evaluation of Immunogenicity and Safety of Human Papillomavirus (HPV) Vaccine Co-administered With Another Vaccine in Healthy Female Subjects | Biotech Hunter | Biotech Hunter